STAT3 and colorectal carcinoma: For example, Xu et al. [19] demonstrated that TIMP-2 promotes 5-FU resistance through JAK-STAT activation, while Pennel et al. [30] identified JAK-STAT3 as a potential therapeutic target in stromal-rich CRC subtypes.